A small biotech company, is developing a groundbreaking therapy for a debilitating, ultra-rare genetic disease. This condition presents a significant unmet medical need, severely affecting early development in infants. Due to the unique nature of the disease, the therapy must be administered in the earliest stages of life, often to newborns, which adds considerable complexity to the clinical development process.
